Literature DB >> 25229257

Association of in vivo κ-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology.

Robert H Pietrzak1,2, Mika Naganawa3, Yiyun Huang3, Stefani Corsi-Travali4,5, Ming-Qiang Zheng3, Murray B Stein6,7, Shannan Henry3, Keunpoong Lim3, Jim Ropchan3, Shu-Fei Lin3, Richard E Carson3, Alexander Neumeister4,5,8.   

Abstract

IMPORTANCE: Exposure to trauma increases the risk for developing threat (ie, fear) symptoms, such as reexperiencing and hyperarousal symptoms, and loss (ie, dysphoria) symptoms, such as emotional numbing and depressive symptoms. While preclinical data have implicated the activated dynorphin/κ-opioid receptor (KOR) system in relation to these symptoms, the role of the KOR system in mediating these phenotypes in humans is unknown. Elucidation of molecular targets implicated in threat and loss symptoms is important because it can help inform the development of novel, mechanism-based treatments for trauma-related psychopathology.
OBJECTIVE: To use the newly developed [11C]LY2795050 radiotracer and high-resolution positron emission tomography to evaluate the relation between in vivo KOR availability in an amygdala-anterior cingulate cortex-ventral striatal neural circuit and the severity of threat and loss symptoms. We additionally evaluated the role of 24-hour urinary cortisol levels in mediating this association. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional positron emission tomography study under resting conditions was conducted at an academic medical center. Thirty-five individuals representing a broad transdiagnostic and dimensional spectrum of trauma-related psychopathology, ranging from nontrauma-exposed psychiatrically healthy adults to trauma-exposed adults with severe trauma-related psychopathology (ie, posttraumatic stress disorder, major depressive disorder, and/or generalized anxiety disorder). MAIN OUTCOMES AND MEASURES: [11C]LY2795050 volume of distribution values in amygdala-anterior cingulate cortex-ventral striatal neural circuit; composite measures of threat (ie, reexperiencing, avoidance, and hyperarousal symptoms) and loss (ie, emotional numbing, major depressive disorder, and generalized anxiety disorder symptoms) symptoms as assessed using the Clinician-Administered PTSD Scale, Hamilton Depression Rating Scale, and Hamilton Rating Scale for Anxiety; and 24-hour urinary cortisol levels.
RESULTS: [11C]LY2795050 volume of distribution values in an amygdala-anterior cingulate cortex-ventral striatal neural circuit were negatively associated with severity of loss (r = -0.39; 95% CI, -0.08 to -0.66), but not threat (r = -0.03; 95% CI, -0.30 to 0.27), symptoms; this association was most pronounced for dysphoria symptoms (r = -0.45; 95% CI, -0.10 to -0.70). Path analysis revealed that lower [11C]LY2795050 volume of distribution values in this circuit was directly associated with greater severity of loss symptoms and indirectly mediated by 24-hour urinary cortisol levels. CONCLUSIONS AND RELEVANCE: Results of this study suggest that KOR availability in an amygdala-anterior cingulate cortex-ventral striatal neural circuit mediates the phenotypic expression of trauma-related loss (ie, dysphoria) symptoms. They further suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-adrenal axis system, as assessed by 24-hour urinary cortisol levels, may indirectly mediate this association. These results may help inform the development of more targeted, mechanism-based transdiagnostic treatments for loss (ie, dysphoric) symptoms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25229257     DOI: 10.1001/jamapsychiatry.2014.1221

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  31 in total

1.  Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence.

Authors:  Sophie E Holmes; Matthew J Girgenti; Margaret T Davis; Robert H Pietrzak; Nicole DellaGioia; Nabeel Nabulsi; David Matuskey; Steven Southwick; Ronald S Duman; Richard E Carson; John H Krystal; Irina Esterlis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

Review 2.  Neuropathology of suicide: recent findings and future directions.

Authors:  P-E Lutz; N Mechawar; G Turecki
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

Review 3.  A Review of the Neurobiological Basis of Trauma-Related Dissociation and Its Relation to Cannabinoid- and Opioid-Mediated Stress Response: a Transdiagnostic, Translational Approach.

Authors:  Ruth A Lanius; Jenna E Boyd; Margaret C McKinnon; Andrew A Nicholson; Paul Frewen; Eric Vermetten; Rakesh Jetly; David Spiegel
Journal:  Curr Psychiatry Rep       Date:  2018-11-07       Impact factor: 5.285

Review 4.  Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.

Authors:  Jonathan DePierro; Lauren Lepow; Adriana Feder; Rachel Yehuda
Journal:  Biol Psychiatry       Date:  2019-07-24       Impact factor: 13.382

5.  Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice.

Authors:  Eduardo R Butelman; Bryan D McElroy; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2019-04-11       Impact factor: 4.030

Review 6.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

7.  Transdiagnostic psychiatry: a systematic review.

Authors:  Paolo Fusar-Poli; Marco Solmi; Natascia Brondino; Cathy Davies; Chungil Chae; Pierluigi Politi; Stefan Borgwardt; Stephen M Lawrie; Josef Parnas; Philip McGuire
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).

Authors:  Miguel Guerrero; Mariangela Urbano; Eun-Kyong Kim; Ana M Gamo; Sean Riley; Lusine Abgaryan; Nora Leaf; Lori Jean Van Orden; Steven J Brown; Jennifer Y Xie; Frank Porreca; Michael D Cameron; Hugh Rosen; Edward Roberts
Journal:  J Med Chem       Date:  2019-02-13       Impact factor: 7.446

10.  Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.

Authors:  Edgardo Falcon; Caroline A Browne; Rosa M Leon; Vanessa C Fleites; Rachel Sweeney; Lynn G Kirby; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2016-03-16       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.